

# DECREASED NK CELL CYTOTOXICITY AND INCREASED T REGULATORY CELLS FACILITATE PROGRESSION OF METASTATIC MURINE MELANOMA

Gordana Radosavljević<sup>1</sup>, Ivan Jovanović<sup>1</sup>, Katerina Martinova<sup>1</sup>, Danijela Živić<sup>2</sup>, Nada Pejnović<sup>1</sup>, Nebojša Arsenijević<sup>1</sup>, Miodrag L. Lukić<sup>1</sup>

<sup>1</sup>Center for Molecular Medicine and Stem Cell Research, Faculty of Medicine, University of Kragujevac, Serbia

<sup>2</sup>Faculty of Medicine, University of Kragujevac, Serbia

## SMANJENA CITOTOKSIČNOST NK ČELIJA I POVEĆANJE REGULATORNIH T LIMFOCITA UBRZAVA METASTAZIRANJE MALIGNOG MELANOMA MIŠA

Gordana Radosavljević<sup>1</sup>, Ivan Jovanović<sup>1</sup>, Katerina Martinova<sup>1</sup>, Danijela Živić<sup>2</sup>, Nada Pejnović<sup>1</sup>, Nebojša Arsenijević<sup>1</sup>, Miodrag L. Lukić<sup>1</sup>

<sup>1</sup>Centar za molekularnu medicinu i istraživanje matičnih ćelija, Fakultet medicinskih nauka Univerziteta u Kragujevcu, Kragujevac, Srbija

<sup>2</sup>Fakultet medicinskih nauka Univerziteta u Kragujevcu, Kragujevac, Srbija

Received / Primljen: 23.03.2012.

Accepted / Prihvaćen: 08. 06. 2012.

### ABSTRACT

*Malignant melanoma is the most aggressive form of skin cancer. Metastatic dissemination in distant organs is one of the hallmarks of melanoma progression. Immunosuppression and tumour escape from immune surveillance are thought to be the major factors responsible for the establishment and progression of melanoma; however, the exact mechanisms leading to decreased anti-tumour immunity are not completely understood. We aimed to analyse the anti-tumour immune response during hematogenous metastasis using a B16-F1 metastatic melanoma model in C57BL/6 mice. At 21 days after tumour cell inoculation, rapid metastatic melanoma growth was observed, reflected through the increased incidence, number and size of metastatic colonies in the lungs (B16-F1). Phenotypic analyses of splenocytes revealed an increased percentage of CD3<sup>+</sup>T cells, a markedly reduced percentage of CD19<sup>+</sup> B cells and an increased percentage and absolute number of CD4<sup>+</sup>Foxp3<sup>+</sup>T regulatory cells. The cytotoxic activities of total splenocytes and isolated NK cells were significantly decreased in tumour-bearing mice. Thus, the metastatic progression of melanoma in this model is associated with diminished NK cytotoxicity, which may be due to an increased expansion of suppressive CD4<sup>+</sup>Foxp3<sup>+</sup> T regulatory cells in the spleen.*

**Keywords:** B16-F1, malignant melanoma, metastasis, NK cells, T regulatory cells

### SAŽETAK

*Maligni melanom je najagresivnija forma tumora kože. Diseminacija metastatskih ćelija u udaljene organe je glavna karakteristika progresije melanoma. Smatra se da su imunosupresija i izbegavanje imunskog nadzora glavni faktori odgovorni za uspostavljanje metastaza, ali precizni mehanizmi odgovorni za oslabljen antitumorski imunski odgovor nisu u potpunosti razjašnjeni. U ovoj studiji, korišćenjem eksperimentalnog modela metastatskog melanoma (B16-F1) u C57BL/6 miševima analizirali smo antitumorski imunski odgovor u toku hematogenih metastatskih procesa. Dvadeset prvog dana nakon ubrizgavanja tumorskih ćelija detektovan je ubrzan rast metastaza malignog melanoma što se ogleda u povećanoj incidenci, broju i veličini metastatskih kolonija u plućima. Fenotipska analiza splenocita ukazuje na povećan procenat CD3<sup>+</sup>T limfocita, značajno smanjene CD19<sup>+</sup> B limfocita i povećan procenat i apsolutan broj regulatornih CD4<sup>+</sup>Foxp3<sup>+</sup>T limfocita. Citotoksička aktivnost ukupnih splenocita i NK ćelija u slezini je statistički značajno smanjena u miševima kojima su ubrizgane ćelije malignog melanoma. Dobijeni rezultati u ovom eksperimentalnom modelu ukazuju da metastatskoj progresiji melanoma značajno doprinosi smanjena ubilačka sposobnost NK ćelija koja je najverovatnije posledica zabeležene ekspanzije imunosupresivnih regulatornih CD4<sup>+</sup>Foxp3<sup>+</sup> T limfocita u slezini.*

**Ključne reči:** B16-F1, maligni melanom, metastaze, NK ćelije, regulatorni T limfociti

UDK: 616-006.81-033.2 / Ser J Exp Clin Res 2012; 13 (3): 85-92

DOI: 10.5937/SJECR13-1726

**Correspondence to:** Gordana Radosavljević, M.D., PhD; Center for Molecular Medicine and Stem Cell Research  
Faculty of Medicine, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia  
Tel: +38134306800; Fax: +38134306800112; E-mail: perun.gr@gmail.com













